Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | RARB | P10826 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22932079 | 0.88 | SMN1; SMN2 (0.67) | SMN1; SMN2KMT2AMEN1RARBHDAC1 | |
| SCHEMBL17169733 | 0.87 | SMN1; SMN2 (0.53) | SMN1; SMN2KMT2AMEN1RARBHDAC1 | |
| SCHEMBL18494088 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2KMT2AMEN1RARBHDAC1 | |
| SCHEMBL19599562 | 0.83 | HDAC1 (0.58) | SMN1; SMN2RARBHDAC1HDAC2RAB9A | |
| SCHEMBL17174025 | 0.83 | L3MBTL1 (0.51) | KMT2AMEN1RARBHDAC1HDAC2 | |
| SCHEMBL20805332 | 0.82 | SMN1; SMN2 (0.48) | SMN1; SMN2KMT2AMEN1RARBHDAC1 | |
| SCHEMBL10018594 | 0.81 | CYP3A4 (0.61) | SMN1; SMN2KMT2AMEN1TSHRHRH3 | |
| SCHEMBL8219820 | 0.81 | SMN1; SMN2 (0.73) | SMN1; SMN2KMT2AMEN1TSHRPOLB | |
| SCHEMBL17174033 | 0.81 | RARB (0.50) | SMN1; SMN2RARBHDAC1HDAC2POLB | |
| SCHEMBL19599647 | 0.81 | CYP3A4 (0.57) | SMN1; SMN2KMT2ARARBHDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230330102-A1 | PROTAC ANTIBODY CONJUGATES AND METHODS OF USE | GENENTECH, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-11666581-B2 | PROTAC antibody conjugates and methods of use | GENENTECH, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11242344-B2 | (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof | GENENTECH, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210309660-A1 | (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2021-10-07 | — | — | US | disclosed |
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-05-07 | — | — | US | disclosed |
| US-20170037004-A1 | ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330102-A1 | PROTAC ANTIBODY CONJUGATES AND METHODS OF USE | PSMA3, PSMA6, PSMA2 | SMN1; SMN2 933/4885KMT2A 1916/4885MEN1 3041/4885 |
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | CRBN, XIAP, RBX1 | SMN1; SMN2 2504/4885KMT2A 1984/4885MEN1 1390/4885 |
| US-20210309660-A1 | (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | VHL, MDM2, CUL2 | SMN1; SMN2 4007/4885KMT2A 1816/4885MEN1 2547/4885 |
| US-11242344-B2 | (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof | VHL, MDM2, CUL2 | SMN1; SMN2 4007/4885KMT2A 1816/4885MEN1 2547/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | SMN1; SMN2 1270/4885KMT2A 2363/4885MEN1 1550/4885 |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | SMN1; SMN2 3500/4885KMT2A 1996/4885MEN1 562/4885 |
| US-11666581-B2 | PROTAC antibody conjugates and methods of use | PSMA3, PSMA6, PSMA2 | SMN1; SMN2 933/4885KMT2A 1916/4885MEN1 3041/4885 |
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | SMN1; SMN2 1838/4885KMT2A 1953/4885MEN1 727/4885 |
| US-20170037004-A1 | ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | XIAP, BIRC3, BIRC2 | SMN1; SMN2 1490/4885KMT2A 3179/4885MEN1 2578/4885 |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | CRBN, CBL, STUB1 | SMN1; SMN2 3500/4885KMT2A 1996/4885MEN1 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.